Drug Profile
Somatostatin-dextran conjugate
Alternative Names: SomaDexLatest Information Update: 17 Sep 2021
Price :
$50
*
At a glance
- Originator DexTech Medical
- Class Antihaemorrhagics; Antineoplastics; Cyclic peptides; Pancreatic hormones; Pituitary hormone release inhibiting hormones
- Mechanism of Action Growth hormone-releasing hormone inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Prostate cancer
Most Recent Events
- 20 Jul 2015 Somatostatin-dextran conjugate is available for licensing as of 20 Jul 2015. http://dextechmedical.com/
- 20 Jul 2015 No recent reports on development identified - Phase-I for Prostate cancer in Mexico and Finland (Parenteral)